149 related articles for article (PubMed ID: 20501505)
61. Capecitabine with weekly paclitaxel for advanced breast cancer: a phase I dose-finding trial.
Uhlmann C; Ballabeni P; Rijken N; Brauchli P; Mingrone W; Rauch D; Pestalozzi BC; Rochlitz C; Aebi S; ;
Oncology; 2004; 67(2):117-22. PubMed ID: 15539915
[TBL] [Abstract][Full Text] [Related]
62. Uncontrolled hypertriglyceridemia induced by capecitabine: case report and review of the literature.
Bar-Sela G; Haim N
Cancer Chemother Pharmacol; 2009 Apr; 63(5):779-82. PubMed ID: 18641989
[TBL] [Abstract][Full Text] [Related]
63. [Tumor specific therapy. Targeted breast cancer therapy].
MMW Fortschr Med; 2003 Sep; 145(38):62. PubMed ID: 14603691
[No Abstract] [Full Text] [Related]
64. Onychomadesis and onycholysis associated with capecitabine.
Chen GY; Chen YH; Hsu MM; Tsao CJ; Chen WC
Br J Dermatol; 2001 Sep; 145(3):521-2. PubMed ID: 11531857
[No Abstract] [Full Text] [Related]
65. Simultaneous 24 h-infusion of high-dose 5-fluorouracil and sodium-folinate as alternative to capecitabine in advanced breast cancer.
Terjung A; Kummer S; Friedrich M
Anticancer Res; 2014 Dec; 34(12):7233-8. PubMed ID: 25503154
[TBL] [Abstract][Full Text] [Related]
66. Influence of capecitabine absorption on its metabolites pharmacokinetics: a bioequivalence study.
Chaigneau L; Royer B; Montange D; Nguyen T; Maurina T; Villanueva C; Demarchi M; Borg C; Fagnoni-Legat C; Kantelip JP; Pivot X
Ann Oncol; 2008 Nov; 19(11):1980-1. PubMed ID: 18952760
[No Abstract] [Full Text] [Related]
67. Are we systematically under-dosing patients with fluorouracil?
Patel K; Iacobuzio-Donahue CA; Gormley PE; Kern SE; Cunningham SC
J Clin Oncol; 2015 Mar; 33(7):e36-7. PubMed ID: 24616306
[No Abstract] [Full Text] [Related]
68. Penetration of capecitabine and its metabolites into malignant and healthy tissue of patients with advanced breast cancer.
Mader RM; Schrolnberger C; Rizovski B; Brunner M; Wenzel C; Locker G; Eichler HG; Mueller M; Steger GG
Int J Clin Pharmacol Ther; 2002 Dec; 40(12):571-2. PubMed ID: 12503818
[No Abstract] [Full Text] [Related]
69. Study on adherence to capecitabine among patients with colorectal cancer and metastatic breast cancer.
Figueiredo Junior AG; Forones NM
Arq Gastroenterol; 2014; 51(3):186-91. PubMed ID: 25296077
[TBL] [Abstract][Full Text] [Related]
70. Potential of capecitabine as first-line therapy for metastatic breast cancer: dosing recommendations in patients with diminished renal function.
O'Shaughnessy JA
Ann Oncol; 2002 Jun; 13(6):983. PubMed ID: 12123346
[No Abstract] [Full Text] [Related]
71. [Onycholysis with hyponychium exudate secondary to chemotherapy with paclitaxel and capecitabine].
Tejera A; Bosch RJ; López N; Herrera E
Actas Dermosifiliogr; 2006 Oct; 97(8):536-8. PubMed ID: 17067535
[TBL] [Abstract][Full Text] [Related]
72. Capecitabine (and 5 fluorouracil) cardiotoxicity. Metabolic considerations.
Lestuzzi C; Tartuferi L; Corona G
Breast J; 2011; 17(5):564-5; author reply 566-7. PubMed ID: 21726348
[No Abstract] [Full Text] [Related]
73. A pilot study: dose adaptation of capecitabine using mobile phone toxicity monitoring - supporting patients in their homes.
Weaver A; Love SB; Larsen M; Shanyinde M; Waters R; Grainger L; Shearwood V; Brooks C; Gibson O; Young AM; Tarassenko L
Support Care Cancer; 2014 Oct; 22(10):2677-85. PubMed ID: 24771299
[TBL] [Abstract][Full Text] [Related]
74. Timing of significant adverse events is essential information during early development of new drugs.
Hyodo I
Int J Clin Oncol; 2006 Feb; 11(1):69; author reply 69-70. PubMed ID: 16508734
[No Abstract] [Full Text] [Related]
75. Brain metastases from HER2-positive breast cancer.
Susheela SP; Revannasiddaiah S; Madhusudhan N; Basavalingaiah A
Lancet Oncol; 2013 Jan; 14(1):e3. PubMed ID: 23276370
[No Abstract] [Full Text] [Related]
76. Brain metastases from HER2-positive breast cancer.
Nieder C
Lancet Oncol; 2013 Jan; 14(1):e2-3. PubMed ID: 23276368
[No Abstract] [Full Text] [Related]
77. Primary systemic treatment of breast-cancer brain metastases.
Bartsch R; Preusser M
Lancet Oncol; 2013 Jan; 14(1):8-9. PubMed ID: 23122783
[No Abstract] [Full Text] [Related]
78. Circadian variations in the pharmacokinetics of capecitabine and its metabolites in rats.
Kobuchi S; Yazaki Y; Ito Y; Sakaeda T
Eur J Pharm Sci; 2018 Jan; 112():152-158. PubMed ID: 29175408
[TBL] [Abstract][Full Text] [Related]
79. Brain metastases from HER2-positive breast cancer - authors' reply.
Bachelot T; Cropet C; Diéras V; Jimenez M; Campone M
Lancet Oncol; 2013 Jan; 14(1):e3-4. PubMed ID: 23276371
[No Abstract] [Full Text] [Related]
80. Response of neoplastic meningitis from solid tumors to oral capecitabine.
Giglio P; Tremont-Lukats IW; Groves MD
J Neurooncol; 2003 Nov; 65(2):167-72. PubMed ID: 14686737
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
